Online:
Visits:
Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Auscann Group Holdings welcomes Canadian company to register

Tuesday, February 14, 2017 20:31
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Auscann Group Holdings (ASX:AC8) has welcomed Canada-based, world leading diversified cannabis company, Canopy Growth Corporation as a substantial shareholder.

Canopy Growth Corporation holds 23 million shares or 10.6% of the company and is the largest legal producer of medicinal cannabis in North America.

Auscann commenced trading on the ASX earlier this month after completing a successful reverse takeover of TW Holdings.

The company raised the maximum $5 million under its prospectus offering by issuing 25 million shares priced at $0.20.

AusCann has a focus on medical cannabis and is well positioned to take advantage of the developing market by bringing together a strong team with relevant and complementary skill sets.

The team also includes Chilean medicinal cannabis grower Fundación Daya.

AusCann has joined the Canopy family of companies and partners that includes Tweed (the most recognised cannabis production brand in the world), Bedrocan, DNA Genetics, Cann Science, Indoor Harvest and Mettrum Health Corp (following its recently announced CAD$430 million acquisition by Canopy).

Use of funds

Given the maximum of $5 million was raised in the prospectus offering, this provides Auscann with total cash of $8.3 million.

Funds are to be allocated as follows:

- Horticulture research and development: $1.8 million
- Chilean joint venture: $1.35 million
- Analytical testing: $0.33 million
- Clinical trials: $2.77 million
- Medical education: $0.33 million
- Licence applications and fees: $0.21 million
- Termination fee: $0.2 million
- Working capital and offer costs: $1.3 million

Background

AusCann believes that patients have the right to high quality, economical and clinically validated cannabis medicines.

AusCann has the ability to deliver these medicines by:

- Having access to expertise and relevant intellectual property in respect of:
- Plant genetics and breeding;
- Cultivation and production techniques;
- Manufacturing techniques;
- Cannabis medicines that are currently being prescribed for patients for a range of conditions internationally;
- Undertaking clinical studies in Australia;
- Having the expertise to operate under Australia’s cultivation and manufacturing requirements; and
- Being able to supply full spectrum plant extracts.

The company’s business model is based upon developing production of medicinal cannabis and partnering with leading researchers.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/173163/auscann-group-holdings-welcomes-canadian-company-to-register-173163.html

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.